Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
10x Genomics, Inc.
TXG
NASDAQ·Healthcare·Medical - Healthcare Information Services·Mkt cap $5.0B
$39.01
▼ -0.10%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$11.16 - $40.08
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 200.2% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
5 reasons
- Proprietary microfluidic chip technology enabling high-throughput single-cell analysis
- Comprehensive integrated platform with complementary solutions (single-cell and spatial)
- Strong recurring revenue model through consumables and reagent sales
- Extensive customer base and installed base creating switching costs
- Continuous innovation pipeline expanding application capabilities
Bear Case
1 risk
- High volatility (beta 2.1). Larger-than-normal price swings expected.
Growth
Stable outlook
Increasing adoption of single-cell analysis in drug discovery and development
Value
Deep value opportunity - significant discount to Healthcare IT & Services peers
Momentum
Hot
+74.9% over 3m
Quality
Excellent
Excellent business quality
Dividend
None
No dividend
Smart-money signal
Who's buying TXG right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: May 6, 2026
MAY 7, 2026
Reported EPS of -$0.10 vs -$0.29 consensus (+65.5% surprise). Revenue of $150.8M vs $146.4M expected (+3.0%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Q2 26
+65.5%
Next: May 6, 2026
Revenue trend · last 8Q
—
—
-10%
+10%
+13%
-2%
+1%
-3%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$153.1M
$151.7M
$165.0M
$154.9M
$172.9M
$149.0M
$166.0M
$150.8M
Margins · last 8Q
Gross
—
Operating
—
Profit
-8.9%
Wall Street consensus
11 analysts · 36% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
36%
Hold
64%
Sell
0%
Median Price Target
$26.00
▼ -33.4% vs $39.01
Latest: Barclays · Jun 24, 2026
2 analysts covering